Zydus Cadila completes enrollment in Evidences III of Saroglitazar Magnesium

18 Jul 2019 Evaluate

Zydus Cadila has completed enrollment in Evidences II, Evidences III and Evidences V Phase 3 clinical trials of Saroglitazar Mg for treating Non-Alcoholic SteatoHepatitis (NASH). Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico.

Evidences II is a Phase3 biopsy-driven trial of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic SteatoHepatitis. Evidences III is the prospective, multicenter, randomized, double-blind study of Saroglitazar4 mg versus Placeboin patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Evidences V will evaluate the NASH patients over a period of 18months, measure the change in the liver fat content by magnetic resonance imaging-derived proton density-fat fraction (MRIPDFF) at Week 24 and evaluate the liver biopsy driven endpoints of Saroglitazar4 mg from baseline to Week 76.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×